Sentences with phrase «in lung cancer cells»

This work showed that the drug was effective in lung cancer cells.

Drugs such as gefitinib and erlotinib are supposed to block those growth signals in lung cancer cells, but not every cancer responds to them.

The Cancer Research UK team, based at the UCL Cancer Institute, has successfully fixed this fault in lung cancer cells — reprogramming the cells to self - destruct.

Cancer Research UK scientists have found a drug combination that can trigger the self - destruct process in lung cancer cells — paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

The Manchester researchers tested a new drug that targets one of these molecules, MCT1, in lung cancer cells and in mouse models.

It is only present at low levels in lung cancer cells which are not metastatic and remain within the lung.

... In lung cancer cell lines, CBD upregulated ICAM - 1, leading to...

In the lung cancer cell shown above at left, red shades indicate the presence of actin, a structural protein important in cell movement.

33) Gandhi J, Zhang J, Xie Y, Shigematsu H, Soh J, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, Lam WL, Garcia M, Minna JD, Gazdar AF (2009) Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

Not exact matches

This drug has already staked its claim in the world of next - gen «checkpoint inhibitor» cancer treatments by besting rival Bristol - Myers Squibb's competing treatment Opdivo in advanced non-small cell lung cancer (NSCLC).

Immune cells modified by CRISPR - Cas9 were inserted into a lung cancer patient at the West China Hospital in Chengdu in the hopes that they'll be able to fight tumors, and 10 people total will receive injections of CRISPR re-engineered cells in order to assess the method's safety.

The medicines, which help unleash the immune system on cancer cells, were tested in patients with advanced lung cancer.

Researchers from the Sichuan University in Chengdu inserted the re-engineered cells into a lung cancer patient participating in a clinical trial at the West China Hospital on October 28th, according to Nature.

The PD - 1 checkpoint inhibitor Keytruda hit its goals in a new trial in previously untreated non-small cell lung cancer patients, beating chemo at staving off cancer progression and extending patients» lives.

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.

They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

In a mid-stage trial, 16 of 37 lung cancer patients given a placebo ahead of standard chemo wound up hospitalized with severely low white blood cell counts.

«We feel it'll be able to help kill cancer cells in 80 percent of breast cancer patients,» said Dr. Olson, who added that their antibody has the potential to help kill lung, colon, prostate and other cancer cells, too.

However, the impact of the two methylation - regulating enzymes was still seen at 10 to 15 months, when scientists found decreased expression of hundreds of genes — many of which are key tumor suppressor genes such as BMP3, SFRP2 and GATA4 — in the smoke - exposed cells and a five - or - more-fold increase in the signaling of the KRAS oncogene that is known to be mutated in smoking - related lung cancers.

Scientists at the Johns Hopkins Kimmel Cancer Center say they have preliminary evidence in laboratory - grown, human airway cells that a condensed form of cigarette smoke triggers so - called «epigenetic» changes in the cells consistent with the earliest steps toward lung cancer develoCancer Center say they have preliminary evidence in laboratory - grown, human airway cells that a condensed form of cigarette smoke triggers so - called «epigenetic» changes in the cells consistent with the earliest steps toward lung cancer develocancer development.

Scientists from Moffitt reported in the Jan. 19 online edition of Cancer Research that nicotine induces the metastatic spread of lung cancer cells by stimulating a protein called beta - arrestiCancer Research that nicotine induces the metastatic spread of lung cancer cells by stimulating a protein called beta - arresticancer cells by stimulating a protein called beta - arrestin - 1.

«Cause of chemoresistance in small cell lung cancer discovered.»

The researchers confirmed this hypothesis by showing that if they blocked YAP1 they could inhibit stem cells from undergoing self - renewal, forming blood vessel - like structures, and reduce lung cancer cell growth in mice.

The modified toxin could treat asthma, in which lung cells secrete too much mucus, and cancers in which cells overproduce cytokines.

They reported that YAP1 is found at high levels in lung cancer stem cells and binds to a protein called OCT4.

The study, published April 4 in the journal The Lancet Oncology, focused on non-small cell lung cancer, which is the most common form of lung cancer.

In the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocyteIn the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytein mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytes.

In a head - to - head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous - non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

The main reason why people die of cancer is that the cancer cells spread to form daughter tumours, or metastases, in vital organs, such as the lungs and liver.

Soon after lung cancer cells (in green) spread into the brain, extracellular matrix molecules (in red) can shield them from the hostile surroundings.

Furthermore, they found that by inhibiting Akt they could significantly slow cell proliferation, cell migration and cell invasion in the lung cancer and bladder cancer cells.

A team led by Lu You, an oncologist at Sichuan University's West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month.

In their latest study, they tested compounds against cells from nine different types of human cancer, including common types affecting blood, colon, breast, prostate, ovaries, kidneys, and lungs.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arcancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, ArCancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

There is currently a PD - 1 antibody on the market that blocks T cell exhaustion in patients with solid tumors, like lung cancer and melanoma.

One, in which Dr. Weiss was the senior author, highlighted the extended survival of metastatic small cell lung cancer (SCLC) patients who received statins.

The current research suggests that pancreatic cancer cells that spread to organs that receive a blood supply rich in glucose and other nutrients, such as the liver and lungs, acquire metabolic adaptations to use these «natural resources» to increase their tumorigenic fitness.

«We'd like to extend this further to examine for driver genes in other types of lung cancer, such as squamous cell lung cancer.»

Among patients who have this type of lung cancer, nearly one in three will carry a particular genetic mutation on their cancer cells.

The scientists identified several, including the investigational cancer drug BEZ235, which blocked a key metabolic pathway in flu - infected human lung epithelial cells.

«CRKII most likely regulates the stability of mutated epidermal growth factor receptors and drives cancer growth by promoting signaling, or communication, within cancer cells,» said Julia Petschnigg, lead author on the paper and a postdoctoral fellow at U of T. «We found that a combinatorial chemotherapy that inhibits those mutated receptors and CRKII could be beneficial in treating lung cancer.»

Stagljar and his colleagues also applied the new technology, which they dubbed MaMTH (for Mammalian - Membrane Two - Hybrid assay), to identify a protein that plays a role in the most common form of lung cancer called non-small cell lung cancer.

Compared to a control (left), epalrestat treatment (right) reduces the number of metastatic tumors (arrowheads) in the lungs of mice injected with human basal - like breast cancer cells.

Although NRF2 has many benefits, loss of NRF2 regulation leads to high levels in certain cancer cells, such as some lung cancers, and it may help them migrate, Zhang says.

Previous studies of genetic alterations in lymphoma and lung cancer have found that certain genetic mutations — specifically when part of a gene breaks off and gets fused to another — can inappropriately switch on ALK, driving cancer cells to grow and divide.

They found out that TiY is capable of distinguishing TICs from non-TICs in various human lung cancer cell lines and patient - derived lung tumors.

Beyond lung cancer, TiY is able to target TICs in 28 types of human cell lines derived from the central nervous system, melanoma, breast, renal, ovarian, colon, and prostate cancer.

«Our study results suggest a new drug cocktail that is effective in both human lung cancer cell lines and fly models,» says Cagan.

But my sharpest memory of those weeks is the helplessness of sitting in a hospital office learning that estrogen receptor - negative breast cancer cells in my sister's body had metastasized to her bones, lungs, and brain.